A 51-year-old woman was referred for thrombophilia testing due to recurrent thromboembolism. She had three episodes of embolism at the age < 50: to the right brachial artery, to the left external iliac artery and common femoral artery with thromboembolectomy and to the right popliteal artery. She was treated with acenocumarol (target international Computer tomography angiography (January 2019) showed large thrombi in several arteries including the ascending aorta despite the use of rivaroxaban and aspirin ( Figure 1A-D) . The patient was referred to vascular and cardiac surgeons for consultations. In March 2019 while on rivaroxaban 20 mg per day and aspirin, ischemic stroke with left sided paresis and aphasia occurred due to the right internal carotid artery occlusion. The patient was switched on apixaban (5 mg twice a day) in combination with low-dose aspirin.
The WES analysis identified a novel heterozygous missense mutation in FGG exon 8: c.998 A>G; p.His333Arg (p.His307Arg without the signal peptide) which we named "Fibrinogen Łódź". This mutation, predicted to be deleterious by SIFT and probably damaging by Polyphen2, affects the same amino acid as "Fibrinogen Mannheim II" [2] Fibrinogen Łódź is unique due to numerous severe arterial thrombotic manifestations below 50 years of age without any venous thrombosis or bleeding and apparent resistance to rivaroxaban. Such clinical phenotype in patients with dysfibrinogenemia is quite uncommon, although 25% of cases of dysfibrinogenemia are associated with mainly venous thrombosis, for example Fibrinogen Dusart [3] . This case suggests that dysfibrinogenemia should be taken under consideration in subjects with arterial thromboembolism at young age. Establishing a proper diagnosis of dysfibrinogenemia allows the initiation of anticoagulant therapy and genetic counselling in asymptomatic family members like in other thrombophilia's [4, 5] .
